Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Lowered by StockNews.com

Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Thursday.

A number of other analysts have also recently issued reports on the stock. Stifel Nicolaus lifted their target price on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Royal Bank of Canada reissued an “outperform” rating and issued a $195.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Truist Financial reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Finally, UBS Group dropped their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, March 1st. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $192.75.

Jazz Pharmaceuticals Stock Up 0.7 %

NASDAQ JAZZ traded up $0.72 during trading on Thursday, reaching $110.01. The company’s stock had a trading volume of 693,769 shares, compared to its average volume of 597,957. The company has a current ratio of 2.27, a quick ratio of 1.85 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $6.94 billion, a PE ratio of 22.68, a PEG ratio of 1.51 and a beta of 0.63. The business has a 50-day moving average price of $116.44 and a 200-day moving average price of $121.10. Jazz Pharmaceuticals has a 1-year low of $103.01 and a 1-year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. On average, research analysts forecast that Jazz Pharmaceuticals will post 16.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Philip L. Johnson bought 12,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was purchased at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vestal Point Capital LP acquired a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $89,175,000. Armistice Capital LLC lifted its position in Jazz Pharmaceuticals by 108.4% during the 4th quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock valued at $80,150,000 after purchasing an additional 338,882 shares during the period. Los Angeles Capital Management LLC lifted its position in Jazz Pharmaceuticals by 558.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock valued at $41,780,000 after purchasing an additional 273,764 shares during the period. Pacer Advisors Inc. lifted its position in Jazz Pharmaceuticals by 28.1% during the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after purchasing an additional 224,865 shares during the period. Finally, Thompson Siegel & Walmsley LLC lifted its position in Jazz Pharmaceuticals by 242.8% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock valued at $35,023,000 after purchasing an additional 191,648 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.